Skip to content
Prof. Dr. Mustafa Özdoğan · Medical Oncologist

The 2020 ASCO Visionary Leader Award went to Dr. Hyman Muss for major contributions to the care of older cancer patients

The 2020 ASCO Visionary Leader Award went to Dr. Hyman Muss for major contributions to the care of older cancer patients

Geriatric oncologist Dr. Hyman B. Muss, who specializes in treating older patients with cancer, has been selected for the American Society of Clinical Oncology's ASCO 2020 Allen S. Lichter Visionary Leader Award.

“Allen S. Lichter Visionary Leader Award” honors people who have achieved revolutionary advances in oncology or inspired others through their leadership and vision in the field. The award was first presented in 2017.

Dr. Hyman B. Muss received this award for his work with geriatric (older) patients. Before beginning Dr. Muss's story, let us share a meaningful quotation from Mustafa Kemal Atatürk: "A nation's attitude toward its older citizens and retirees is the most important measure of that nation's capacity to live."

Starting Out in Geriatric Oncology: How Much Remains Unknown About Older People

About 25 years ago, at Wake Forest School of Medicine, Muss entered this field under William R. Hazzard's mentorship. With their teachers' guidance, he and fellow resident Kathy L. Christman conducted one of the first studies comparing chemotherapy tolerability and outcomes in older patients with those in younger patients with metastatic breast cancer. ‘‘This paper really surprised me,’’ he would later recall. ‘‘My God, we know so little about people in this age group.’’

The study would be published in one of the leading medical journals, JAMA (the Journal of the American Medical Association). It would then pave the way for similar studies in older patients with cancer.

Another Study That Left Its Mark on Oncology

The second major milestone in his career came when he joined the Alliance for Clinical Trials in Oncology. This led to the formation of the first committee focused on cancer in older patients. “We completed one of the first studies evaluating adjuvant (postoperative preventive) chemotherapy in older women,” he said. Specifically designed to compare standard chemotherapy with oral chemotherapy, the study showed that standard chemotherapy was more effective in this group of patients. The data were published in 2009 by NEJM (New England Journal of Medicine).

Dedication and a Passion for Research

Throughout his professional career, Dr. Hyman B. Muss has worked to improve the care of older patients in oncology through his own hospital, the Southern Oncology Association, the American Board of Internal Medicine and multiple ASCO committees. He has received many professional awards during his career. Today, he continues his professional service without interruption.

The first of his current projects examines the adverse effects of modern chemotherapy regimens in older adults. They collect patient-reported data and assess how they can intervene to help patients have a better experience with chemotherapy.

For women aged 70 and older who have completed breast cancer treatment, his second project focuses on improving their quality of life. “We are looking from a geriatric assessment perspective to see whether we can intervene in these patients' quality of life,” Dr. Muss says. “Unfortunately, with the shortage of geriatricians and family physicians in this country, many older people with correctable problems tend to get lost in the system.”

Their third line of research focuses on aging biomarkers and their role in predicting treatment-related toxicity (adverse effects) and comorbidity (coexisting illness).

Tackling the Challenges in Geriatric Oncology

Although geriatric oncology has made substantial progress over the past few decades, Dr. Muss notes that clinical trials still face some major challenges. He adds that overcoming these challenges requires completing more studies in older people and using large datasets.

He also says that the small number of geriatric oncologists and the lack of sufficient funding for geriatricians specializing in this field are major obstacles to progress.

“Geriatricians are one of the most valuable resources we have in healthcare; however, they are few in number and, in my opinion, are not adequately rewarded for all their wonderful efforts.”

Sources

1. Christman K, Muss HB, Case LD, et al. Chemotherapy of Metastatic Breast Cancer in the Elderly. The Piedmont Oncology Association Experience [See Comment]. JAMA 1992.

2. Muss HB, Berry DA, Cirrincione CT, et al. Adjuvant Chemotherapy in Older Women with Early-Stage Breast Cancer. N Engl J Med 2009.

3. ASCO Honors Geriatric Oncologist Dr. Hyman B. Muss with the Allen S. Lichter Visionary Leader Award. dailynews.ascopubs.org. 6 May 2020

Appointment request

DROZDOGAN AI

Explore this article together

Ask about the article and read answers alongside published sources from our site.

DROZDOGAN AI

Drozdogan Assistant

The 2020 ASCO Visionary Leader Award went to Dr. Hyman Muss for major contributions to the care of older cancer patients

Ask about the article and read answers alongside published sources from our site.

Conversation and privacy information

Drozdogan Assistant answers this conversation. Authorized site administrators may review it for quality. Do not share personal information.

Replies use OpenAI infrastructure. Questions and replies are processed by that service; conversation records are stored on our site. Do not share identifying, contact or personal health information.

0 / 1000

For information only; no personal diagnosis or treatment advice.

Related articles

Explore other articles on this topic.

Stay informed

Receive new articles and scientific updates by email.

Google Analytics runs on public pages independently of this window and may use analytics cookies. Your choice here controls external services only.

Cookie policy